ArticleJournal for immunotherapy of cancer2022
Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer.
Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- ELISPOT as a Functional for Biomarker Study in Cancer Immunotherapy: Applications and Future Directions.International journal of molecular sciences · 2026Pooled it
- Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade.International journal of molecular sciences · 2026Review
- Cancer vaccines: comprehensive review.BJS open · 2026Review
- RNA-based cancer vaccines: mechanisms, clinical progress, and translational challenges.Immunologic research · 2025Review
- LAMA3 overexpression enhances proliferation, migration and invasion in esophageal squamous cell carcinoma based on bioinformatics and experimental validation.Scientific reports · 2025Article
- Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review).International journal of oncology · 2025Review
- Thioredoxin: a key factor in cold tumor formation and a promising biomarker for immunotherapy resistance in NSCLC.Respiratory research · 2025Article
- Review
- Advances in the application of tumor vaccines and combination strategies: new perspectives in lung cancer treatment.Frontiers in immunology · 2025Review
- Cancer vaccines: advances, hurdles, and future directions.Exploration of targeted anti-tumor therapy · 2025Review
- Identification of potential biomarkers and drug of ischemic stroke in patients with COVID-19 through machine learning.Heliyon · 2024Article
- Identification of mutations in canine oral mucosal melanomas by exome sequencing and comparison with human melanomas.Scientific reports · 2024Article
- Tumor Neoepitope-Based Vaccines: A Scoping Review on Current Predictive Computational Strategies.Vaccines · 2024Article
- Comprehensive profiling of cancer neoantigens from aberrant RNA splicing.Journal for immunotherapy of cancer · 2024Article
- Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties.Nature cancer · 2024Article
- Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens.Frontiers in immunology · 2024Article
- Recent advances in neoantigen vaccines for treating non-small cell lung cancer.Thoracic cancer · 2023Review
- The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.Molecular cancer · 2023Review
- Cell-free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients.Molecular oncology · 2023Article
- Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model.Journal for immunotherapy of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 5 countries.
Funding
Abstract
backgroundCancer is characterized by an accumulation of somatic mutations, of which a significant subset can generate cancer-specific neoepitopes that are recognized by autologous T cells. Such neoepitopes are emerging as important targets for cancer immunotherapy, including personalized cancer vaccination strategies.
methodsWe used whole-exome and RNA sequencing analysis to identify potential neoantigens for a patient with non-small cell lung cancer. Thereafter, we assessed the autologous T-cell reactivity to the candidate neoantigens using a long peptide approach in a cultured interferon gamma ELISpot and tracked the neoantigen-specific T-cells in the tumor by T-cell receptor (TCR) sequencing. In parallel, identified gene variants were incorporated into a Modified Vaccinia Ankara-based vaccine, which was evaluated in the human leucocyte antigen A*0201 transgenic mouse model (HHD).
resultsSequencing revealed a tumor with a low mutational burden: 2219 sequence variants were identified from the primary tumor, of which 23 were expressed in the transcriptome, involving 18 gene products. We could demonstrate spontaneous T-cell responses to 5/18 (28%) mutated gene variants, and further analysis of the TCR repertoire of neoantigen-specific CD4
conclusionsOur study demonstrates the feasibility of efficiently identifying tumor-specific neoantigens that can be targeted by vaccination in tumors with a low mutational burden, promising successful clinical exploitation, with trials currently underway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.